Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
CHARGE Prognostic Index (HRCAs, hyperferritinemia, anemia, early relapse (<18 mos from frontline), ECOG ≥2) & exposure to prior BCMA-directed tx) may identify RRMM pts at risk for early treatment failure w/ bispecifics.”
Title: Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Authors: Saurabh Zanwar, Doris K. Hansen, Oren Pasvolsky, Carlyn Tan, Lauren C. Peres, Utkarsh Goel, Rakesh Popat, Aimaz Afrough, Sireesha Asoori, Masooma Rana, Mrugakshi Dave, Andrew Portuguese, Efstathios Kastritis, James A. Davis, Joaquin Martinez-Lopez, Douglas Sborov, Jana Mihalyova, Susan Bal, Murali Janakiram, Darren Pan, Leyla Shune, Christopher Ferreri, Noa Biran, Megan Herr, Ariel Grajales-Cruz, Jack Khouri, Andre De Menezes Silva Corraes, Omar Castaneda Puglianini, Emily C. Liang, Eli Zolotov, Tiffany Richards, Mahmoud Gaballa, Gliceida Galarza Fortuna, Kelley Julian, Kimberly Green, Aishwarya Sannareddy, Larry D. Anderson Jr., Shahzad Raza, Danai Dima, Lekha Mikkilineni, Faiz Anwer, Shaji Kumar, Saad Usmani, Chiung-Yu Huang, Hira Mian, Surbhi Sidana, Krina Patel, Thomas Martin, Yi Lin, Luciano Costa.
You can read the full article on Journal of Clinical Oncology.
You can find other articles featuring Robert Orlowski on OncoDaily.
